UK markets open in 2 hours 28 minutes

Roche Holding AG (0QQ6.IL)

IOB - IOB Delayed price. Currency in CHF
Add to watchlist
310.400.00 (0.00%)
At close: 04:19PM BST
Full screen
Previous close310.40
Open312.80
Bid0.00 x N/A
Ask0.00 x N/A
Day's range309.20 - 313.40
52-week range309.20 - 389.76
Volume825
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022

    New positive data from Evrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapy programme for Duchenne muscular dystrophy (DMD), a progressive disease that leads to premature death, reinforce confidence in the most advanced Phase 3 study currently underwayStudy designs of two new trials in generalised myasthenia gravis (gMG), a rare chronic autoimmune disease, and facioscapulohumeral muscular dystrophy (FSHD), a genet

  • Globe Newswire

    Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU

    Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible for a targeted treatment, which could significantly improve their outcomes.1,2The PATHWAY anti-HER2 (4B5) test is the only FDA approved companion diagnostic indicated as an aid in the assessment of HER2 low status in metastatic breast cancer patients. These patients may now consider ENHERTU as a treatment option based on the results of the Pha

  • Globe Newswire

    [Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023

    Basel, 3 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Matt Sause (45), currently Head of Roche Diagnostics’ North America Region, will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023. Thomas Schinecker, the incumbent CEO of the Diagnostics Division and new Roche CEO as of 15 March 2023: “Matt Sause’s career at Roche has spanned twenty years in multiple countries across Asia, Latin America, Europe and North America